Mutation analysis in a patient with mild hyperphenylalaninaemia showed three distinct base substitutions in exon 12 of the phenylalanine hydroxylase (PAH) gene. All three mutations, R413P, Y414C, and D415N, have previously been described as being independently associated with PAH deficiency. Family studies and independent analysis of the PAH alleles of the patient showed cosegregation of the R413P and Y414C mutations. Data on the ethnic background of the family provide evidence that the R413P mutation has occurred on a PAH allele carrying the Y414C mutation. Using current methods for mutation identification, the presence of two known mutations on a single PAH allele implies the risk of misdiagnosis of PAH deficiency and complicates genetic counselling. Our results stress the need for comprehensive mutation scanning of the PAH gene in diagnostic settings.
The liver enzyme phenylalanine hydroxylase (PAH, EC 1.14.16.1) catalyses the irreversible conversion of L-phenylalanine to L-tyrosine. Deficiency of PAH activity leads to hyperphenylalaninaemia and, without dietary treatment, usually causes mental retardation. The degree of enzyme impairment is highly variable. This is reflected in a broad span of biochemical and clinical phenotypes, ranging from classical phenylketonuria (PKU) to Improved methods of detection and identification ofmutations have made DNA analysis a powerful tool for diagnosis of PAH deficiency. 10 In routine diagnostic settings, the identification of two known mutations in a newborn with raised blood levels of phenylalanine would generally be sufficient to establish PAH deficiency as the cause of hyperphenylalaninaemia, and to predict the metabolic phenotypic outcome.4 This is not always true, however, and in this paper we describe a patient with hyperphenylalaninaemia who has three known mutations. The implications of this observation for molecular diagnosis and genetic counselling are discussed.
Materials and methods

SAMPLES
The proband is a 13 year old girl with MHP. She was born after an uneventful pregnancy by normal, term, spontaneous delivery. Her birth weight was 2980 g. She was breast fed and had a normal neonatal course. Her newborn blood screen at the age of 3 days indicated a phenylalanine level of 600 jimol/l (10 mg/dl) (determined by the Guthrie bacterial inhibition assay"). activity has not been evaluated in vitro. In the hyperphenylalaninaemic patient described in this paper, the R413P and Y414C mutations were inherited in cis, and the D415N mutation was inherited in trans. This pattern of inheritance is compatible with the MHP phenotype in the proband owing to the dominance of the "mild" allele (D415N) over the potentially "severe" allele (R413P-Y414C) .4
The origin of the R413P-Y414C allele is not clear. The location of the two base substitutions, separated by only two base pairs, renders recombination highly unlikely. Since both mutations occur on haplotype 4,1617 it is not possible to determine the nature of the origin of the R413P-Y414C allele by molecular means. The proband's father, who carries the R413P-Y414C allele, however, is of European descent, indicating that the original chromosome probably carried the Y414C mutation and the double mutation resulted from occurrence of the R413P mutation. The hypermutability hypothesis supports this suggestion. In contrast to the Y414C mutation, the R413P mutation involves a CpG dinucleotide, which has a 8-5 times higher mutation rate than that of the average dinucleotide'9 and is known to be a mutation "hot spot" in a wide range of human genes, including the PAH gene. 20 The frequency of the R413P-Y414C allele in European populations is not known. Hitherto, the majority of Y414C alleles have been identified by searching for this mutation using diagnostic mutation detection techniques, for example, allele specific oligonucletide (ASO) probing, or digestion with restriction endonucleases.2' These methods do not provide information about other sequence alterations in the PAH gene and will generally not allow recognition of the R413P mutation. Re-examination of Y414C bearing chromosomes by sequence analysis would determine the actual frequency of the R413P-Y414C allele. Although this could turn out to be a frequent PKU allele in some populations, investigation of more than 60 European chromosomes carrying the Y414C mutation has not revealed cosegregation with the R413P mutation in any case (unpublished results), indicating that the R413P-Y414C allele is probably rare in Europe. This is in agreement with previous results, showing the absence of the R413P mutation from 50 European mutant chromosomes.'6 The only demonstration of the R413P mutation in Europe is from The Netherlands,6 but no indication of its frequency or its possible cosegregation with the Y4 1 4C mutation has been reported.
As indicated above, the R413P mutation is associated with classical PKU, while the Y4 1 4C mutation is associated with mild PKU. Therefore, coinheritance of the two mutations in trans would be expected to result in a mild PKU phenotype, and a phenylalanine restricted diet would be implemented. In contrast, the phenotypic outcome in a patient with the R413P and Y414C mutations inherited in cis is strongly dependent on the mutation inherited in trans. If the latter mutation is associated with classical PKU, a severe phenotype results and requires rigorous treatment, whereas if it is associated with MHP, as in the present case, the phenotypic outcome is MHP with no need for treatment. Consequently, accurate prognosis and considerations of therapy require complete genotyping and correct interpretation of the genotype. Current methods for detection and identification of point mutations are based on PCR amplification of target DNA and will not always allow discrimination between the two alleles. 
